Elevate Standard of Care with Preemptive Pharmacogenomics (PGx) Testing
Whole Pharmacogenomics Scan (WPSTM) is the most comprehensive, customizable, and scalable preemptive PGx test which can analyze nearly all actionable pharmacogenetic genes of a patient with a single, one-time test.1
WPS IMPROVES PATIENT OUTCOMES AND REDUCES COSTS
Guides choice of medications and dosing based on genetic profile
18% of all the prescriptions in the U.S. are affected by actionable PGx genes2,3
90-99% of the population has high-risk variant for at least one established PGx gene4,5
Multiple genes may affect the response of a drug and each gene/drug combination has a different level of evidence and actionability.
We guide our customers to integrate the correct level of PGx information that meets their system’s needs and provides actionable clinical value to their patients.
Provides deep coverage of genetic variants, including many rare alleles that are not identified by most other assays with analysis of duplications/deletions, complex structural arrangements, and copy number information.
Leads to more accurate and precise genotyping/ phenotyping of each PGx gene, including complex genes, such as CYP2D6
Enables the detection of many rare genotypes which is critical when diagnosing patients from diverse populations
WPS customers can build their unique precision medicine program by beginning with one or multiple medical conditions or focusing on a particular group of patients. WPS knowledge base can be expanded to meet additional medical conditions and patient groups as the program grows.
By creating a patient’s PGx database, WPS enables continuous re-analysis of a patient’s PGx profile and updates clinical recommendations as new clinical guidelines and evidence become available to guide choice of medications and dosing.
Customers can choose the genes/drugs combinations that provide the best value to their patients with WPS four-tier system.
We work closely with each customer to create a customized clinical report that best aligns with their medical practice and also adjust the clinical report as their teams and practices evolve.
Instituting WPS preemptive testing
Allows patient’s PGx profile to be available before clinical decisions are made regarding future medications
Informs potentially life-threatening decisions regarding best treatment options
Is cost effective since one test can potentially meet a patient’s life-long PGx needs
WPS CLINICAL REPORTS
Test results come in two reports:
Comprehensive PGx report based on patient’s WPS profile.
Individualized and actionable clinical recommendations based on the patient’s WPS profile and medication list.*
Gene/drug pairs categorized based on levels of actionability and evidence.
Use individual’s genomic profile and medication history to potentially fulfill individual’s life-long PGx needs.
Select the desired gene/drug pairs that work the best for each clinical practice.
Use clinical evidence curated by the experts at RPRD, from CPIC guidelines,9 FDA label information10 and other peer-reviewed scientific studies.11
Work with customers toward EMR data integration and clinical decision support.
A leading U.S. pediatric hospital:
Utilizing preemptive PGx for patient care using WPS and its predecessor since 20119,10
Nearly 4,500 patients have benefited from the program as of November 201811
Keys To Successful WPS Implementation9
Get institutional support
Partner with a knowledgable clinical laboratory
Develop a process to manage any incidental findings
Develop a strategy to educate clinicians and patients
Develop a process to return results
Extensive use of informatics, especially clinical decision support, integrated to EHR
Relling MV, et al. Pharmacogenomics in the Clinic. Nature. 2015 Oct;526(7573):343-50.
Ji Y, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol. Diagn. 2016 May;18(3):438-46.
Dunnenberger HM, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015 Jan;55:89-106.